0001735276-21-000097.txt : 20211223
0001735276-21-000097.hdr.sgml : 20211223
20211223172308
ACCESSION NUMBER: 0001735276-21-000097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211221
FILED AS OF DATE: 20211223
DATE AS OF CHANGE: 20211223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaishnaw Akshay
CENTRAL INDEX KEY: 0001458494
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 211518161
MAIL ADDRESS:
STREET 1: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2021-12-21
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001458494
Vaishnaw Akshay
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE
MA
02142
0
1
0
0
President, R&D
Common Stock
2021-12-21
4
A
0
5417
0.0
A
16632
D
Common Stock
2021-12-22
4
F
0
2415
189.13
D
14217
D
Common Stock
2021-12-22
4
F
0
1
190.5
D
14216
D
Common Stock
2021-12-22
4
F
0
122
186.48
D
14094
D
Common Stock
2021-12-23
4
S
0
124
186.22
D
13970
D
Common Stock
2021-12-23
4
S
0
137
187.08
D
13833
D
Common Stock
2021-12-23
4
S
0
130
187.35
D
13703
D
Common Stock
2021-12-23
4
S
0
127
188.26
D
13576
D
Common Stock
2021-12-23
4
S
0
73
189.01
D
13503
D
Common Stock
2021-12-23
4
S
0
8
189.18
D
13495
D
Common Stock
2021-12-23
4
S
0
144
189.24
D
13351
D
Common Stock
2021-12-23
4
S
0
144
190.02
D
13207
D
Common Stock
2021-12-23
4
S
0
5
190.27
D
13202
D
Common Stock
2021-12-23
4
S
0
73
190.33
D
13129
D
Common Stock
2021-12-23
4
S
0
142
190.39
D
12987
D
Common Stock
2021-12-23
4
S
0
125
190.86
D
12862
D
Common Stock
2021-12-23
4
S
0
1000
191.45
D
11862
D
Common Stock
2021-12-23
4
S
0
73
192.25
D
11789
D
Common Stock
2021-12-23
4
S
0
126
193.37
D
11663
D
Common Stock
2021-12-23
4
S
0
145
193.67
D
11518
D
Common Stock
2021-12-23
4
S
0
303
195.11
D
11215
D
Common Stock
515
I
by Managed Account
On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
All sales reported on this Form 4, other than the sell-to-cover for taxes on December 22, 2021, were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2021.
Sale prices ranged from $191.14 to $191.80.
Sale prices ranged from $194.82 to $195.43.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
By: /s/ Mary Beth DeLena, Attorney-in-Fact For: Akshay K. Vaishnaw
2021-12-23